About Robert Baffi
Robert Baffi is a venture partner at Samsara BioCapital, a life sciences investment company. He joined the firm in March 2021. Baffi has served on Neuvivo's board since 2024; Neuvivo is testing an immune therapy for amyotrophic lateral sclerosis, or ALS. He joined Neurogene's board in December 2023 after serving on Neurogene OpCo's board from September 2020 to December 2023.
At BioMarin, Baffi worked from May 2000 through March 2023. He led global manufacturing and technical operations from 2018 to 2020, then became senior adviser to the chairman and chief executive officer in 2021. Earlier, he spent 14 years at Genentech and held research roles at Cooper BioMedical and Becton Dickinson Research Center. His work helped 28 products gain approval and commercial success. His former boards include Mosaic ImmunoEngineering and Bionic Sight. He remains an emeritus science adviser to the National Institute for Bioprocessing Research & Training. He earned biochemistry degrees at City University of New York and an MBA at Regis University. He wrote Making a Habit of Quality about technical operations in drug development.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Robert Baffi in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Robert Baffi works with at each company, as listed on that company's latest Form D.